Randomized, open naturalistic, acute treatment of panic disorder with clonazepam or paroxetine

Journal of Clinical Psychopharmacology

Volumn 31, Issue 2, 2011, Pages 259-261

  Nardi, Antonio E ^a   Valença, Alexandre M ^a   Freire, Rafael C ^a   Amrein, Roman ^a   Sardinha, Aline ^a   Levitan, Michelle N ^a   Nascimento, Isabella ^a   De Melo Neto, Valfrido L ^a   King, Anna L ^a   De O E Silva, Adriana C ^a,b   Veras, André B ^a   Dias, Gisele P ^a   Soares Filho, Gastão L ^a,c   Da Costa, Rafael T ^a   Mezzasalma, Marco A ^a   De Carvalho, Marcele R ^a   De Cerqueira, Ana C ^a   Hallak, Jaime E ^d   Crippa, José A ^d   Versiani, Marcio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c Pró Cardý́aco Hospital ^*  (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; FLUOXETINE; PAROXETINE;

ADULT; AGORAPHOBIA; APPETITE DISORDER; BODY WEIGHT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAMILTON ANXIETY SCALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NATURALISTIC INQUIRY; NAUSEA AND VOMITING; OPEN STUDY; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SWEAT GLAND DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; XEROSTOMIA;

ADOLESCENT; ADULT; CLONAZEPAM; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PAROXETINE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952437127     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318210b4ee     Document Type: Letter

References (13)

1. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord. 2005;88:27-45. (Pubitemid 41160411)
2. Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol. 1997;17:390-400. (Pubitemid 27414395)
3. Sheehan DV, Burnham DB, Iyengar MK, et al. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry. 2005;66:34-40.
4. Nardi AE, Freire RC, Valença AM, et al. Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol. 2010;30:290-293.
5. Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry. 1999;60:604-612. (Pubitemid 29451557)
6. Valença AM, Nardi AE, Nascimento I, et al. Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr. 2000;58:1025-1029.
7. Nardi AE, Valença AM, Nascimento I, et al. A three-year follow-up study of patients with the respiratory subtype of panic disorder after treatment with clonazepam. Psychiatr Res. 2005;137:61-70. (Pubitemid 41550129)
8. Dannon PN, Lowengrub K, Iancu I, et al. Paroxetine in panic disorder: clinical management and long-term follow-up. Expert Rev Neurother. 2004;4:191-198. (Pubitemid 38315939)
9. Shader RI, Greenblatt DJ. Approaches to the treatment of anxiety states. In: Shader R, ed. Manual of Psychiatric Therapeutics. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:184-209.
10. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(suppl 5):7-12.
11. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. Am J Psychiatry. 1998; 155(suppl 5):1-34.
12. Pollack MH, Simon NM, Worthington JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. 2003;17:276-282. (Pubitemid 37150836)
13. Marks DM, Park MH, Ham BJ, et al. Paroxetine: safety and tolerability issues. Expert Opin Drug Saf. 2008;7:783-794.